-
Je něco špatně v tomto záznamu ?
New fluorine-containing hydrazones active against MDR-tuberculosis
Eva Vavříková, Slovenko Polanc, Marijan Kočevar, Kata Horváti, Szilvia Bősze, Jiřina Stolaříková, Kateřina Vávrová, Jarmila Vinšová
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS10367
MZ0
CEP - Centrální evidence projektů
- MeSH
- antituberkulotika chemie metabolismus farmakologie MeSH
- buněčné linie MeSH
- fluor chemie metabolismus farmakologie MeSH
- hydrazony chemie metabolismus farmakologie MeSH
- krevní plazma metabolismus MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- multirezistentní tuberkulóza farmakoterapie MeSH
- Mycobacterium kansasii účinky léků MeSH
- Mycobacterium účinky léků MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Several new fluorine-containing hydrazones were synthesized and screened for their in vitro antimycobacterial activity. Nine of these derivatives have shown a remarkable activity against MDR-TB strain with MIC 0.5 μg/mL and high value of selectivity index (SI). Compound 3h with the highest SI (1268.58) was used for stability evaluation with putative metabolites (ciprofloxacin and formylciprofloxacin) detection. Compound 3h was stable at pH 7.4 of aqueous buffer and rat plasma, in acidic buffers (at pH 3 and 5) slow decomposition was observed. Interestingly, no formylciprofloxacin was detected in the solution, and only slightly increased concentration of ciprofloxacin was observed instead. Trifluoromethyl hydrazones 3f and 3g exhibited the best activity also against two strains of Mycobacterium kansasii (MIC 1-4 μmol/L). All evaluated compounds were found to be non-cytotoxic.
Institute of Public Health Centre of Hygienic Laboratories Ostrava Czech Republic
University of Ljubljana Faculty of Chemistry and Chemical Technology Ljubljana Slovenia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022267
- 003
- CZ-PrNML
- 005
- 20160324104219.0
- 007
- ta
- 008
- 120806s2011 fr f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2011.07.052 $2 doi
- 035 __
- $a (PubMed)21855181
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Vavříková, Eva $7 xx0126311 $u Charles University, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, Hradec Králové, Czech Republic
- 245 10
- $a New fluorine-containing hydrazones active against MDR-tuberculosis / $c Eva Vavříková, Slovenko Polanc, Marijan Kočevar, Kata Horváti, Szilvia Bősze, Jiřina Stolaříková, Kateřina Vávrová, Jarmila Vinšová
- 520 9_
- $a Several new fluorine-containing hydrazones were synthesized and screened for their in vitro antimycobacterial activity. Nine of these derivatives have shown a remarkable activity against MDR-TB strain with MIC 0.5 μg/mL and high value of selectivity index (SI). Compound 3h with the highest SI (1268.58) was used for stability evaluation with putative metabolites (ciprofloxacin and formylciprofloxacin) detection. Compound 3h was stable at pH 7.4 of aqueous buffer and rat plasma, in acidic buffers (at pH 3 and 5) slow decomposition was observed. Interestingly, no formylciprofloxacin was detected in the solution, and only slightly increased concentration of ciprofloxacin was observed instead. Trifluoromethyl hydrazones 3f and 3g exhibited the best activity also against two strains of Mycobacterium kansasii (MIC 1-4 μmol/L). All evaluated compounds were found to be non-cytotoxic.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antituberkulotika $x chemie $x metabolismus $x farmakologie $7 D000995
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a fluor $x chemie $x metabolismus $x farmakologie $7 D005461
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrazony $x chemie $x metabolismus $x farmakologie $7 D006835
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a Mycobacterium $x účinky léků $7 D009161
- 650 _2
- $a Mycobacterium kansasii $x účinky léků $7 D019909
- 650 _2
- $a krevní plazma $x metabolismus $7 D010949
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a multirezistentní tuberkulóza $x farmakoterapie $7 D018088
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Polanc, Slovenko $u University of Ljubljana, Faculty of Chemistry and Chemical Technology, Ljubljana, Slovenia
- 700 1_
- $a Kočevar, Marijan $u University of Ljubljana, Faculty of Chemistry and Chemical Technology, Ljubljana, Slovenia
- 700 1_
- $a Horváti, Kata $u Eötvös Loránd University, Research Group of Peptide Chemistry, Hungarian Academy of Science, Budapest, Hungary
- 700 1_
- $a Bosze, Szilvia $u Eötvös Loránd University, Research Group of Peptide Chemistry, Hungarian Academy of Science, Budapest, Hungary
- 700 1_
- $a Stolaříková, Jiřina $7 xx0142458 $u Institute of Public Health, Centre of Hygienic Laboratories, Ostrava, Czech Republic
- 700 1_
- $a Vávrová, Kateřina $7 xx0118201 $u Charles University, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, Hradec Králové, Czech Republic
- 700 1_
- $a Vinšová, Jarmila, $d 1951- $7 nlk19990073991 $u Charles University, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, Hradec Králové, Czech Republic
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 46, č. 10 (2011), s. 4937-4945
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21855181 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20160324104247 $b ABA008
- 999 __
- $a ok $b bmc $g 944180 $s 779564
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 46 $c 10 $d 4937-4945 $e 20110805 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- GRA __
- $a NS10367 $p MZ0
- LZP __
- $b NLK111 $a Pubmed-20120806/12/01
